Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Med Oncol ; 40(6): 163, 2023 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-37115331

RESUMEN

BACKGROUND: Ameloblastoma in 66% of the cases harbor a somatic mutation of the "mitogen-activated protein kinase" signaling pathway (BRAF V600E). In V600E mutations, BRAF is in the permanent "on" state and relays the growth-promoting signals independently of the EGFR pathway. Therefore, mutant BRAF represents a target for handful of new drugs. METHODS: We conducted a literature search, with the search terms "Vemurafenib, Dabrafenib, Ameloblastoma, and BRAF." These included seven case reports with nine patients who underwent monotherapy with Dabrafenib or Vemurafenib or combination therapy with Dabrafenib and Trametinib. RESULTS: The patients age ranges from 10 years up to 86 years. The distribution of women and men is 4:5. Patients with an initial diagnosis of ameloblastoma, as well as recurrences or metastasized ameloblastoma were treated. Indications cover neoadjuvant therapy up to the use in metastasized patients in an irresectable state. Results ranging from "only" tumor size reduction to restitutio ad integrum. CONCLUSION: We see the use of BRAF Inhibitors to reduce tumor size with consecutive surgical treatment as a reasonable option for therapy. However, we are aware that at present the data are based only on case reports with the longest follow-up of just 38 months. We encourage further clinical trials in the use of BRAF Inhibitors for selecting ameloblastoma patients in a multi-center setting.


Asunto(s)
Ameloblastoma , Proteínas Proto-Oncogénicas B-raf , Masculino , Humanos , Femenino , Niño , Vemurafenib , Proteínas Proto-Oncogénicas B-raf/genética , Ameloblastoma/tratamiento farmacológico , Ameloblastoma/genética , Ameloblastoma/inducido químicamente , Imidazoles/uso terapéutico , Imidazoles/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéutico , Mutación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
3.
Gan ; 66(3): 319-21, 1975 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1181232

RESUMEN

Four cases of ameloblastic odontomas were found in the Long-Evans rats treated with multiple oral administration of a heavy dose of N-butylnitrosourea. The tumor was found as an expansive enlargement over the mandible and was roentgen-opaque. The tumor was histologically characterized by various elements such as odontogenic epithelium, stellated reticulum tissue, enamel, and/or dentine, and was classified as ameloblastic odontoma.


Asunto(s)
Ameloblastoma/inducido químicamente , Carcinógenos , Neoplasias Mandibulares/inducido químicamente , Compuestos de Nitrosourea , Tumores Odontogénicos/inducido químicamente , Animales , Femenino , Masculino , Neoplasias Experimentales/inducido químicamente , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...